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Abstract
Introduction and hypothesis We studied the feasibility and
efficacy of intravesical instillations with 40 ml chondroitin
sulfate 0.2% solution to prevent or reduce acute radiation
cystitis in women undergoing pelvic radiotherapy.
Methods In a comparative pilot study in 20 patients, half of
the patients received instillations. Instillations' bother was
measured with visual analog scores (VAS, 0–10); bladder
pain, with VAS; micturition-related quality of life, with the
urogenital distress inventory (UDI).
Results One of the instilled patients discontinued the instilla-
tions. The first median “acceptability”-VAS was 0 (range, 0–
3); the last median was 1 (range, 0–3). “Bladder pain”-VAS
peaked halfway in the treatment among controls (median, 1;
range,0–5)andaftertreatmentintheinstilledpatients(median,
1; range, 1–3). UDI scores showed over time median follow-
up scores at or above median baseline scores in controls and
at or below median baseline scores in instilled patients.
Conclusion Intravesical instillations with chondroitin sul-
fate 0.2% solution may decrease the bother related to
bladder symptoms and are well tolerated.
Keywords Acute radiation cystitis.0.2% Chondroitin
sulfate.Intravesical instillations.Overactive bladder.
Pelvic radiotherapy
Abbreviations
RC Radiation cystitis
GAG layer Glucosamino-glycane layer
UDI Urogenital distress inventory
VAS Visual analog scale
T=0 Time point before radiotherapy
T=4 Time point in the fourth week of radiotherapy
T=8 Time point after radiotherapy
RCT Randomized clinical trial
Introduction
Acute radiation cystitis (RC) is a common and debilitating
problem in patients undergoing radiotherapy for gyneco-
logical malignancies [1]. Acute RC symptoms develop on
average at 2 to 3 weeks after the start of treatment in up to
24–30% of patients, and these symptoms include painful
micturition, urgency, frequency, and nocturia [1, 2]. These
overactive bladder symptoms are known to seriously impair
quality of life [3]. Although this acute condition is claimed
to be self-limiting, it may result in chronic RC, which
carries the risk of life-threatening morbidity [4–6]. Treat-
ment of acute RC is only symptomatic, and up to now, no
preventive measures have been studied.
The pathophysiology of acute RC is not exactly clear,
but the bladder wall is internally built up by fast-dividing
uroepithelium, susceptible to radiation damage. The uroe-
pithelium is coated by the glucosamino-glycane (GAG)
M. H. Hazewinkel (*): J.-P. W. R. Roovers
Department of Obstetrics and Gynecology,
Academic Medical Center,
Amsterdam, The Netherlands
e-mail: m.h.hazewinkel@amc.uva.nl
L. J. A. Stalpers
Department of Radiotherapy, Academic Medical Center,
Amsterdam, The Netherlands
M. G. Dijkgraaf
Department of Clinical Epidemiology and Biostatistics,
Academic Medical Center,
Amsterdam, The Netherlands
Int Urogynecol J (2011) 22:725–730
DOI 10.1007/s00192-010-1357-0layer, preventing urinary irritants to reach the underlying
sensory nerves. When the uroepithelium is damaged, this
results in insufficiency of the GAG layer, and consequently,
silent C-fibers are depolarized by urinary irritants, leading
to RC symptoms [5, 7]. Acute RC usually occurs 3 to
6 weeks after starting radiation therapy [5]. Up to 3 months
after the start of radiation therapy, the occurrence of RC is
often called the acute form [4, 8].
Endometrial and cervical malignancies can be treated
with primary or adjuvant pelvic radiotherapy. The mode of
treatment depends on disease-related characteristics, such as
size and extension of the tumor and, to a lesser extent, on
patient characteristics [8, 9]. The severity of morbidity
during and after treatment depends on the radiotherapy
dosage and volume [9, 10]. Since the radiation schedule is
determined by disease-related characteristics, the preven-
tion of acute RC can therefore not easily be accomplished
by lowering the dose and volume but should be sought for
direct protection of the bladder.
Based on animal studies demonstrating that intravesical
instillation with chondroitin sulfate solution is capable of
coating a damaged bladder wall, we hypothesize that
prophylactic instillations on patients undergoing radiother-
apy for gynecologic malignancies may limit the risk of
distressing RC symptoms [11]. Our hypothesis is supported
by the observation that in interstitial cystitis (IC) patients,
GAG layer replenishment therapy has been proven to be
effective [12, 13]. By keeping the coating of the urothelium
intact during the radiotherapy treatment, the cells could be
less damaged by urinary irritants. Short-term protection of
the GAG layer and thus limitation of the risk on acute RC
might even reduce the risk on chronic RC which has even
more decrementing effects, although this possible long-term
effect is outside the scope of this pilot study.
Instillation with chondroitin sulfate has no known
adverse effects but is time-consuming and possibly burden-
some, and most patients will need the assistance of a health-
care professional to undergo instillations.
The aims of this pilot study were to investigate the
feasibility and efficacy of intravesical instillations with
chondroitin sulfate 0.2% solution to prevent or reduce acute
RC in patients treated with pelvic radiotherapy for
gynecological cancer.
Patients and methods
We performed a comparative pilot study to evaluate the
feasibility and efficacy of chondroitin sulfate 0.2% solution to
preventorreduceRCinendometrialorcervicalcancerpatients
who did and did not receive instillations. The study was
performed between September 2007 and September 2009 in
the Academic Medical Center Amsterdam, The Netherlands.
We included patients who met the following criteria:
aged 18 years or older, planned for primary or adjuvant
radiotherapy for endometrial or cervical cancer and able to
complete a Dutch questionnaire. We excluded patients who
were planned to only undergo brachytherapy, patients with
previous surgery of the lower urinary tract or patients with a
(suprapubic) catheter in situ.
We used 40-ml 0.2% solution of chondroitin sulfate
(Gepan® instill) for the intravesical instillations (Pohl-
Boskamp, Hohenlockstedt, Germany). In accordance with
comparative studies in IC patients, we planned weekly
instillations during the 6 weeks that radiotherapy lasted
[13]. The study coordinator (MH) did the instillations at the
radiotherapy outpatient clinic after a course of radiotherapy,
as patients had to have a full bladder before undergoing
radiotherapy and were allowed to empty the bladder
afterwards. These instillations were planned 2 days after
chemotherapy, if applicable, as the hyperhydration during
and the day after chemotherapy might have an influence on
the effect of the intravesical instillation. A single-use
catheter with an outer-side diameter of 4 mm (12 Ch) was
used to first empty the bladder and then fill the bladder with
the 40 ml solution. Patients were asked not to void at least
2 h after the instillation.
We included 20 uterine or cervical cancer patients
consecutively at the outpatient department before start of
treatment. Ten patients consented to have weekly intra-
vesical instillations and ten consented to participate as
control patients. The control group only completed the set
of questionnaires. Choice of treatment was left at the
discretion of the patient until the planned total of ten
patients per group was reached.
During 8 weeks, i.e. before, during and after radiother-
apy, patients weekly completed the questionnaires: four
questions to quantify the acceptability of the intervention
using visual analog scale (VAS) scores ranging from 0 to
10, with lower scores indicating higher acceptability. These
questions were about distress: from coming to the outpa-
tient clinic to receive the instillation, from the insertion of
the single-use catheter for the instillation, from holding the
instilled fluid in the bladder after instillation and from the
instillation in total. Five questions using VAS scores were
asked to measure bladder pain related to voiding: bladder
pain at the moment when urge starts, just before voiding,
during voiding, just after emptying the bladder, when not
having the urge to void or just after voiding. The urogenital
distress inventory (UDI) measured quality of life related to
micturition. The UDI has five symptom domains, with
scores ranging from 0 to 100, with a higher score
corresponding with more bother of that symptom [14].
Descriptive statistics are reported.
Adverse effects of chondroitin sulfate are not clearly
known. The substance is not absorbed into the body. In one
726 Int Urogynecol J (2011) 22:725–730study, a mild rash has been mentioned, but furthermore, no
serious complications related to chondroitin sulfate admin-
istered intravesically have been described [12]. Because of
the risk of developing urinary tract infection (UTI) when
regularly catheterizing, we checked with a urine culture
when the radiotherapist had clinical suspicion of UTI.
This study was approved by the local medical ethical
committee. The participants signed an informed consent.
Results
Ten patients had intravesical instillations. One patient,
treated with radiotherapy and hyperthermia, discontinued
the instillations after week 4 due to urethral pain, and she
refused to complete the subsequent questionnaires.
The median age of the instillation group was 55 years
(range, 32–75), and that of the controls was 64 years
(range, 47–93). For more patient characteristics, see
Table 1.
The “acceptability of instillations”-VAS had a median
score of 0 (range, 0–3) after the first instillation and a
median of 1 (range, 0–3) at week 6 (last instillation).
“Bladder pain”-VAS levels peaked at week 4 among the
controls (median, 1; range, 0–5) and at week 8 in the
instillation group (median, 1; range, 1–3) (data not shown).
Table 2 shows the symptom scores of both groups before
(T=0), halfway (T=4) and after (T=8) radiotherapy.
Intervention group, N=10 Control group, N=10
Age (median, range) 55 (32–75) 64 (47–93)
Uterine cancer Endometrial 4 7
Carcinosarcoma 1
FIGO stage IC G2 1
IIA G2 1 IC G3 1
IIIA 1 IIA G3 1
IIIC G2 1 IIB G2 1
Recurrence
a 1 IIIA G1 1
Carcinosarcoma IC 1 IVB 1
Unknown
a 1
Surgery AUE+BSO 3 AUE+BSO 4
AUE±LND 1 AUE±LND 2
AUE+BSO+LND 1
Postoperative RT (Grays) (46) 4 (46) 4
(48.6) 1 (48.6) 2
Primary RT (Grays) (40.05) 1
Brachytherapy (Grays) (10) 3 (10) 5
(12) 1
Chemotherapy 2
Cervical cancer 5 3
FIGO stage IBI 1 IBI 2
IB2 1 IIIB 1
IIB 2
IIIB 1
Surgery LNDebulking 3 RH+LND 1
VH 1
Postoperative RT (Grays) (46) 3 (46) 2
Primary RT (Grays) (46) 2 (46) 1
Brachytherapy (Grays) (24) 5 (10) 1
(24) 1
(28) 1
Hyperthermia 1 h/week 1 1
Surdosage parametria/LN 4 2
Chemotherapy 4 1
Table 1 Characteristics of
study groups (numbers of
patients, unless indicated
otherwise)
G grade of tumor cell differen-
tiation, AUE abdominal hyster-
ectomy, BSO bilateral salpingo-
oophorectomy, LND lymph
node dissection, RT radiothera-
py, LNDebulking lymph node
debulking, RH+LND radical
hysterectomy and lymph node
dissection, VH vaginal hysterec-
tomy–cervical cancer was coin-
cidentally found, FIGO
international federation of
gynaecologic oncology, LN
lymph nodes
a Recurrence–previous treatment
did not include radiotherapy, only
AUE and BSO
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follow-up scores at or above median baseline scores in
controls and at or below median baseline scores in the
instillation group for overactive bladder, incontinence and
obstructive voiding, respectively.
During the radiotherapy treatment period, urine was
cultured for five patients of the instillation group and four
of the control group. None of the instillation patients and
one patient of the control group had a UTI.
Discussion
We observed a clear trend towards less bothersome
overactive bladder–urinary incontinence–and obstructive
micturition symptoms in women who had bladder
instillations with chondroitin sulfate 0.2% solution during
pelvic radiotherapy treatment for cervical or endometrial
cancer. Added to our observation that these instillations
are well tolerated, the group of patients receiving
instillations reported less distress from overactive bladder
symptoms during the period of radiotherapy compared to
controls.
Some limitations of this pilot study need to be discussed.
First, the number of included patients is limited. Before the
start of this study, the tolerability and the efficacy of the
instillations for this indication were unknown. We per-
formed the study to generate a hypothesis about this
possibly new preventive measure, and therefore, the limited
number of included patients was appropriate. Moreover,
even though the sample size was small, less distress from
urogenital symptoms was reported by patients that had the
experimental treatment.
The absence of randomization could also be seen as a
limitation of our study. Our primary aim, however, was to
evaluate the feasibility of an intervention in patients who
undergo a demanding treatment at the same time. As
questions arose about the willingness to undergo instilla-
tions within the research group, we came to the agreement
to give patients a choice to receive the instillations accept-
ing the selection bias.
The heterogeneous treatment modalities are the final
limitations we would like to address. Different types of
hysterectomy are known to be associated with different
bladder or voiding dysfunctions [15, 16]. The uterine
cancer patients in the instillation and control groups were
comparable in surgical treatments. The difference between
cervical cancer patients in the two study groups was that
radical hysterectomy and vaginal hysterectomy were per-
formed in the control group, and only lymph node
debulking without radical hysterectomy was performed in
the instillation group. We do not expect more bladder
symptoms in the control group because of the hysterecto-
mies, as the instillation group undergoing lymph node
debulking had larger tumors, which might cause overactive
bladder symptoms as well. Furthermore, we excluded
patients who used a catheter to void to have some
indication of a good bladder function before radiotherapy.
The strength of our study is that, even though these
patients undergo very intense treatment, they mostly
completed the intensive study protocol receiving the
instillations and completing the questionnaires. This might
be explained by the patients' eagerness to prevent any
possible side effect and by the tolerability of instillations.
The control group in this study only completed the
questionnaires, without a direct gain from the study, but
were very compliant in completing the questionnaires.
Another strength of our study is that we used validated
pelvic floor-related quality of life questionnaires to measure
the urogenital symptoms, measuring for the first time these
symptoms in patients currently treated for gynecological
malignancies.
A final remark that could be made about this study is
that the intervention group is younger than the controls
and therefore might have less urogenital symptoms. An
explanation for the age difference could be that younger
Table 2 Urogenital distress inventory (UDI) domain scores
T=0 T=4 T=8
Median (range) Median (range) Median (range)
Instillation (n=10) Control (n=7) Instillation (n=9) Control (n=6) Instillation (n=7) Control (n=7)
OAB 22 (0–66) 11 (0–55) 11 (0–33) 38 (0–55) 22 (0–66) 33 (0–55)
INC 25 (0–50) 17 (0–33) 0 (0–50) 17 (0–83) 0 (0–50) 33 (0–83)
OBS 0 (0) 0 (0–66) 0 (0–33) 25 (0–66) 0 (0–17) 17 (0–33)
PAIN 0 (0–50) 0 (0–33) 0 (0–33) 8 (0–17) 0 (0–33) 0 (0–17)
The range of each domain score was 0–100; a higher score indicating more distress
T=0 measurementbeforethestartofradiation,T=4measurement in the fourth week of radiation, T=8measurement in the eighth week after the start
of radiation and radiotherapy had ended, OAB overactive bladder, INC incontinence, OBS obstructive voiding, PAIN painful bladder/pelvic area
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effects than older patients with instillations. Above that,
the intervention group started with higher symptom
scores than the controls, which pleads against younger
age being associated with less bother of symptoms.
Obviously, a randomized clinical trial (RCT) should be
performed to evaluate whether age is a risk factor for more
symptoms. We felt, from an ethical point of view, that the
feasibility of the instillations had to be examined in these
patients prior to an RCT. The refusal to continue the
instillations of only one patient due to urethral pain after
the fourth instillation makes the instillations seem a
feasible intervention.
As the urogenital symptoms were less bothersome in
the intervention group than in the control group, we will
try to explain this. The current policy for patients with
acute RC symptoms is usually conservatively with
analgesics and anticholinergics [6]. Therefore, we cannot
compare our results with those of previous studies.
Chondroitin sulfate 0.2% solution has been studied before
in the chronic cystitis condition, including RC [13]. The
pathophysiology of chronic and acute RC is different,
which makes the results also difficult to compare to ours.
The probable working mechanism of the intravesical
instillations with chondroitin sulfate 0.2% solution to
prevent or reduce acute RC is that the impermeability of
the urothelium for urinary irritants is sustained by coating
it with the chondroitin sulfate [11]. By protecting the
urothelium from these irritants, the acute bothersome
symptoms do not occur or when they occur, do so to a
lesser extent. The largest difference between the instilla-
tion and control groups in bother of overactive bladder
symptoms, expressed by the UDI domain score OAB, was
found in the fourth week of treatment. At that time,
patients had received 4 weeks of radiotherapy. Acute
symptoms occur 3 to 6 weeks after the start of radiother-
apy [5]. It could be that the instillation group had the most
beneficial effect during the 6 weeks of instillation and that,
after the end of the radiation treatment and the six
instillations, this effect decreased.
Conclusion
The results of this pilot study show that intravesical
instillations with chondroitin sulfate 0.2% solution are well
tolerated by patients undergoing pelvic radiotherapy for a
gynecological malignancy. Additionally, the instillations
appear to reduce overactive bladder symptoms during the
period of radiotherapy. Whether the restricted severity of
symptoms following radiotherapy can be entirely explained
by the effectiveness of chondroitin sulfate itself or by other
factors such as additional attention that was given to the
intervention group, this needs to be assessed by a double-
blind placebo-controlled RCT. If confirmed, the evaluated
intervention could be the first described preventive mea-
surement for the occurrence of acute RC. If the observation
would hold true in future studies, this could implicate a
major improvement of quality of life in women undergoing
radiotherapy.
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